Fatigue

FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

Retrieved on: 
Friday, February 16, 2024

"Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).

Key Points: 
  • "Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).
  • Melanoma can spread to other parts of the body if not detected and treated early, resulting in metastatic disease.
  • Treatment for unresectable or metastatic melanoma may include immunotherapy using PD-1 inhibitors, which are antibodies targeting certain proteins in the body to help the immune system fight off cancer cells.
  • Those patients whose melanoma has progressed with these therapies have a high unmet medical need.

Capsulyte Unveils PREGAME: The Ultimate Solution for Party Recovery, Marking Its Debut at DC Fashion Week

Retrieved on: 
Friday, February 16, 2024

CRANBURY, N.J., Feb. 16, 2024 /PRNewswire/ -- Capitalizing on cutting-edge ingredients, Capsulyte's PREGAME has emerged as the most advanced product to aid in party recovery and address symptoms often associated with hangovers. As a significant milestone for the brand, Capsulyte has been invited to participate in the prestigious DC Fashion Week, a testament to the company's alignment with premium lifestyles and the fashion industry's elite. This invitation further underscores Capsulyte's commitment to excellence and positions PREGAME as the preferred choice for discerning individuals seeking to enjoy social occasions to the fullest, without the next-day regrets.

Key Points: 
  • As a significant milestone for the brand, Capsulyte has been invited to participate in the prestigious DC Fashion Week, a testament to the company's alignment with premium lifestyles and the fashion industry's elite.
  • Many individuals face the unpleasant reality of hangover symptoms such as headaches, fatigue, and nausea, resulting from alcohol consumption.
  • These effects can be primarily attributed to acetaldehyde, a toxic compound that is created when the liver metabolizes alcohol.
  • As the brand marks its presence at DC Fashion Week, Capsulyte is set to redefine the standards of social indulgence and wellness.

Herbal medicinal product: Cimicifugae rhizomaArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of black cohosh.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing black cohosh.
  • Black cohosh preparations may also be found in combination with other herbal substances in some herbal medicines.
  • - Therapeutic area
    - Urinary tract and genital disorders
    - Status
    - C: ongoing call for scientific data
    - Date added to the inventory
    - Date added to priority list
    - Outcome of European assessment
    - European Union herbal monograph

Fear Free® and Blue Heron Consulting announce a Strategic Alliance

Retrieved on: 
Thursday, February 15, 2024

DENVER, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Fear Free® and Blue Heron Consulting announce a Strategic Alliance.

Key Points: 
  • DENVER, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Fear Free® and Blue Heron Consulting announce a Strategic Alliance.
  • Blue Heron Consulting agrees that the value a Fear Free certification adds to a practice is undeniable.
  • This alliance marks a significant milestone in both company's missions to transform the veterinary industry by integrating Fear Free principles with Blue Heron Consulting's strategic expertise.
  • "We're excited to align with Blue Heron Consulting to enhance veterinary practices," said Randy Valpy, CEO of Fear Free.

Festool Unveils New Drywall Sander for the Modern Professional: Setting New Standard for the Drywall Sanding Experience

Retrieved on: 
Thursday, February 15, 2024

LEBANON, Ind., Feb. 15, 2024 /PRNewswire/ -- Festool, a leading manufacturer of innovative, precision-engineered, and durable power tool solutions, today announced new sanding and abrasive solutions for drywallers and painters, along with a new guide rail set designed to meet the needs of woodworkers. Available beginning March 15, 2024, the PLANEX LHS 2-M Drywall Sander (PLANEX M), two abrasive combo kits, and FS 1400/2-KP Guide Rail Starter Set are designed to enhance efficiency and improve finish results on the jobsite and in the shop.

Key Points: 
  • PLANEX LHS 2-M Drywall Sander: The Specialist for Smooth Walls & Ceilings
    The Planex M redefines the sanding pattern with its easy-to-use interface.
  • The ergonomic design is highly controllable and comfortable while being able to reach most surfaces.
  • With a working length of 55-inches and an ergonomic T-shaped handle, it is comfortable to handle and well-suited for standard room height.
  • Starting March 15, 2024, the PLANEX LHS 2-M Drywall Sander (577359) will be available starting at $999.00.

NDT and Inspection Market worth $18.4 billion by 2029- Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 15, 2024

The power Generation vertical of the NDT and Inspection market is predicted to register the highest market share between 2024-2029.

Key Points: 
  • The power Generation vertical of the NDT and Inspection market is predicted to register the highest market share between 2024-2029.
  • NDT and Inspection market for the Asia Pacific region to register the highest CAGR between 2024 and 2029 forecast.
  • The Asia Pacific region is poised to emerge as the fastest-growing market for NDT and inspection, driven by rapid infrastructural developments.
  • However, challenges such as pricing pressures pose a limitation to the growth of the NDT and inspection industry in Asia Pacific.

NDT and Inspection Market worth $18.4 billion by 2029- Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 15, 2024

The power Generation vertical of the NDT and Inspection market is predicted to register the highest market share between 2024-2029.

Key Points: 
  • The power Generation vertical of the NDT and Inspection market is predicted to register the highest market share between 2024-2029.
  • NDT and Inspection market for the Asia Pacific region to register the highest CAGR between 2024 and 2029 forecast.
  • The Asia Pacific region is poised to emerge as the fastest-growing market for NDT and inspection, driven by rapid infrastructural developments.
  • However, challenges such as pricing pressures pose a limitation to the growth of the NDT and inspection industry in Asia Pacific.

More Americans are Feeling Fatigued; MegaFood Launches 3-in-1 Iron Energy Gummies to Power Your Days

Retrieved on: 
Thursday, February 15, 2024

* While the Blood Builder iron supplements were developed for people with iron deficiency, MegaFood Iron Energy Gummies offers a lower potency formula with a moderate 4 mg of iron per serving to support the whole family's energy needs.

Key Points: 
  • * While the Blood Builder iron supplements were developed for people with iron deficiency, MegaFood Iron Energy Gummies offers a lower potency formula with a moderate 4 mg of iron per serving to support the whole family's energy needs.
  • *
    Since 60% of Americans report feeling fatigued,1 MegaFood is developing products to support healthy energy levels.
  • With over 40 years of experience expertly crafting iron supplements, MegaFood's Iron Energy Gummies are a solution for the whole family.
  • Iron Energy Gummies are non-GMO, vegan, gluten-free, and made with pectin and only 1 g of sugar per serving.

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Retrieved on: 
Thursday, February 15, 2024

TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.

Key Points: 
  • TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.
  • Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing.
  • In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.
  • "The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable" said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Retrieved on: 
Thursday, February 15, 2024

TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.

Key Points: 
  • TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.
  • Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing.
  • In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.
  • "The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable" said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.